EverSource Wealth Advisors LLC Raises Holdings in Johnson & Johnson (NYSE:JNJ)

Key Points

• EverSource Wealth Advisors LLC has increased its stake in Johnson & Johnson by 10.5%, now holding 19,646 shares valued at approximately $3.26 million.
• Johnson & Johnson's quarterly earnings report showed $2.77 EPS, surpassing analyst estimates, with revenue of $23.74 billion, reflecting a year-over-year increase of 5.8%.
• The company announced a quarterly dividend of $1.30 per share, representing a 2.9% dividend yield, with a payout ratio of 55.61%.

EverSource Wealth Advisors LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,646 shares of the company's stock after purchasing an additional 1,863 shares during the quarter. EverSource Wealth Advisors LLC's holdings in Johnson & Johnson were worth $3,258,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Elios Financial Group Inc. boosted its holdings in Johnson & Johnson by 1.5% in the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock valued at $746,000 after purchasing an additional 66 shares in the last quarter. Atlantic Family Wealth LLC boosted its holdings in Johnson & Johnson by 4.4% in the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after purchasing an additional 67 shares in the last quarter. MBA Advisors LLC boosted its holdings in Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after purchasing an additional 68 shares in the last quarter. Sovereign Financial Group Inc. boosted its holdings in Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after purchasing an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc boosted its holdings in Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after purchasing an additional 69 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 1.2%

Shares of JNJ stock opened at $176.76 on Friday. The business's 50 day moving average is $161.28 and its two-hundred day moving average is $158.34. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $177.27. The company has a market capitalization of $425.70 billion, a P/E ratio of 18.90, a price-to-earnings-growth ratio of 2.23 and a beta of 0.41. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company's revenue was up 5.8% on a year-over-year basis. During the same period last year, the business posted $2.82 EPS. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Analyst Ratings Changes

JNJ has been the subject of a number of research analyst reports. Barclays upped their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Guggenheim restated a "neutral" rating and set a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Bank of America raised their price target on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Finally, Royal Bank Of Canada raised their price target on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.